CareLit Fachartikel

Cost-effectiveness of angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers in newly diagnosed type 2 diabetes in Germany

CC Adarkwah, A Gandjour · Diabetologie und Stoffwechsel · 2011 · Heft 08

Dokument
1170466
CareLit-ID
Jahr
2011
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig

Bibliografische Angaben

Zeitschrift
Diabetologie und Stoffwechsel
Autor:innen
CC Adarkwah, A Gandjour
Ausgabe
Heft 08 / 2011
Seiten
–
Erschienen: 2011-08-29 00:00:00
ISSN
1861-9002
DOI
10.1055/s-0031-1280949

Zusammenfassung

Objective: Type 2 diabetes is the main cause of end-stage renal disease (ESRD) in Europe and the USA. Angiotensin-converting enzyme (ACE) inhibitors slow down the progression of renal disease and therefore provide a renal-protective effect. However, uncertainty exists concerning the best time to start with ACE-inhibitor therapy. Furthermore, about 10% of patients develop ACE-inhibitor induced cough and thus are eligible for more expensive angiotensin II receptor blockers (ARBs). The aim was to assess the most cost-effective time to start an ACE inhibitor (or ARB therapy in the event of cough) in patients with ty…

Schlagworte

Angiotensin Angiotensin II Germany Diabetes Mellitus Diagnosis After Angiotensin-Converting Enzyme Inhibitors Diabetologie und Stoffwechsel